Use of the Indigo CAT RX aspiration system during percutaneous coronary intervention.
aspiration thrombectomy
penumbra
percutaneous coronary intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
revised:
30
01
2024
received:
19
10
2023
accepted:
16
02
2024
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
29
2
2024
Statut:
aheadofprint
Résumé
The use of the Indigo CAT RX Aspiration System (Penumbra Inc.) during percutaneous coronary intervention has received limited study. We retrospectively examined the clinical, angiographic, and procedural characteristics, outcomes, and follow-up of patients who underwent mechanical aspiration thrombectomy with the Indigo CAT RX system (Penumbra Inc.) at a large tertiary care hospital between January 2019 and April 2023. During the study period, 83 patients (85 lesions) underwent thrombectomy with the Indigo CAT RX. Mean patient age was 64.9 ± 14.48 years and 31.2% were women. The most common presentations were ST-segment elevation myocardial infarction (MI) (66.2%) and non-ST-segment elevation MI (26.5%). A final thrombolysis in MI flow grade of 3 and final myocardial blush grade of 3 were achieved in 76% and 46% of the cases, respectively. Technical success was achieved in 88.9% of the cases that included Indigo CAT RX treatment only, compared with 57.1% of the cases that also included manual aspiration. There were no device-related serious adverse events. At 30-day postprocedure, the incidence of major adverse cardiac events (composite of cardiovascular death, recurrent MI, cardiogenic shock, new or worsening New York Heart Association Class IV heart failure, stroke) was 8.5%: 1.3% stroke (postprocedure, in-hospital), 1.3% MI, 6.1% cardiac death, and 7.5% developed cardiogenic shock. Use of the Indigo CAT RX system is associated with high technical success and acceptable risk of complications, including stroke.
Sections du résumé
BACKGROUND
BACKGROUND
The use of the Indigo CAT RX Aspiration System (Penumbra Inc.) during percutaneous coronary intervention has received limited study.
METHODS
METHODS
We retrospectively examined the clinical, angiographic, and procedural characteristics, outcomes, and follow-up of patients who underwent mechanical aspiration thrombectomy with the Indigo CAT RX system (Penumbra Inc.) at a large tertiary care hospital between January 2019 and April 2023.
RESULTS
RESULTS
During the study period, 83 patients (85 lesions) underwent thrombectomy with the Indigo CAT RX. Mean patient age was 64.9 ± 14.48 years and 31.2% were women. The most common presentations were ST-segment elevation myocardial infarction (MI) (66.2%) and non-ST-segment elevation MI (26.5%). A final thrombolysis in MI flow grade of 3 and final myocardial blush grade of 3 were achieved in 76% and 46% of the cases, respectively. Technical success was achieved in 88.9% of the cases that included Indigo CAT RX treatment only, compared with 57.1% of the cases that also included manual aspiration. There were no device-related serious adverse events. At 30-day postprocedure, the incidence of major adverse cardiac events (composite of cardiovascular death, recurrent MI, cardiogenic shock, new or worsening New York Heart Association Class IV heart failure, stroke) was 8.5%: 1.3% stroke (postprocedure, in-hospital), 1.3% MI, 6.1% cardiac death, and 7.5% developed cardiogenic shock.
CONCLUSIONS
CONCLUSIONS
Use of the Indigo CAT RX system is associated with high technical success and acceptable risk of complications, including stroke.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The authors are grateful for the philanthropic support of our generous anonymous donors, and the philanthropic support of Drs. Mary Ann and Donald A Sens; Mrs. Dianne and Dr. Cline Hickok; Mrs. Wilma and Mr. Dale Johnson; Mrs. Marilyn and Mr. William Ryerse; Mr. Greg and Mrs. Rhoda Olsen; Mrs. Charlotte and Mr. Jerry Golinvaux Family Fund; the Roehl Family Foundation; the Joseph Durda Foundation. The generous gifts of these donors to the Minneapolis Heart Institute Foundation's Science Center
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Burzotta F, Trani C, Romagnoli E, et al. Manual thrombus-aspiration improves myocardial reperfusion. J Am Coll Cardiol. 2005;46(2):371-376. doi:10.1016/j.jacc.2005.04.057
Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117(24):3152-3156. doi:10.1161/CIRCULATIONAHA.107.742312
Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557-567. doi:10.1056/NEJMoa0706416
Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369(17):1587-1597. doi:10.1056/NEJMoa1308789
Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372(15):1389-1398. doi:10.1056/NEJMoa1415098
Jolly SS, James S, Džavík V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction. Circulation. 2017;135(2):143-152. doi:10.1161/CIRCULATIONAHA.116.025371
Mathews SJ, Parikh SA, Wu W, et al. Sustained mechanical aspiration thrombectomy for high thrombus burden coronary vessel occlusion: the multicenter CHEETAH study. Circ Cardiovasc Interv. 2023;16(2):e012433. doi:10.1161/CIRCINTERVENTIONS.122.012433
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction. Circulation. 2001;103(21):2550-2554. doi:10.1161/01.CIR.103.21.2550
TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial. N Engl J Med. 1985;312:932-936. doi:10.1056/NEJM198504043121437
van 't Hof AWJ, Liem A, Suryapranata H, Hoorntje JCA, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Circulation. 1998;97(23):2302-2306. doi:10.1161/01.CIR.97.23.2302
Levine GN, Bates ER, Blankenship JC, et al. ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2015;133(11):1135-1147. doi:10.1161/CIR.0000000000000336
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):4. doi:10.1161/CIR.0000000000001039
Gilchrist IC, Fordham MJ, Pyo R, Reilly JP, Chen O. Mechanical aspiration thrombectomy using the penumbra CAT RX system for patients presenting with acute coronary syndrome. Cardiovasc Revasc Med. 2022;40:316-321. doi:10.1016/j.carrev.2021.06.130
Tashtish N, Chami T, Dong T, et al. Routine use of the “penumbra” thrombectomy device in myocardial infarction: a real-world experience-ROPUST study. J Interv Cardiol. 2022;2022:e5692964. doi:10.1155/2022/5692964
Hahn J, Jeon J, Geum MJ, et al. Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis. Thromb J. 2023;21(1):76. doi:10.1186/s12959-023-00519-x
Niu XW, Zhang JJ, Bai M, Peng Y, Zhang Z. Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis. J Geriatr Cardiol. 2017;14(10):614-623. doi:10.11909/j.issn.1671-5411.2017.10.002